We know that positive safety and efficacy data from ACTIV-5 will be sent to the UK's MHRA, and perhaps to Europe's EMA. But France and Normandy, in particular, seemed interested in lenz. And maybe supportive ACTIV-5 data will get Humanigen to re-engage with Cenexi.
There's just a lot to do, including in Australia, and perhaps only about 3 weeks to get it done, or at least to begin getting regulatory approval from somewhere.
Of course, a successful short squeeze, to wring those 110M air shares out of our market, will relieve the company's financial burden. It may even restore my financial constraints, and graduate me from a life of existence, back to one of normalcy.
News 
Market Data 
Discover 
